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Abstract
Background: Precision medicine is set to deliver a rich new data set of genomic information. However, the number
of certified specialists in the United States is small, with only 4244 genetic counselors and 1302 clinical geneticists. We
conducted a national survey of 264 medical professionals to evaluate how they interpret genetic test results,
determine their confidence and self-efficacy of interpreting genetic test results with patients, and capture their
opinions and experiences with direct-to-consumer genetic tests (DTC-GT).
Methods: Participants were grouped into two categories, genetic specialists (genetic counselors and clinical
geneticists) and medical providers (primary care, internists, physicians assistants, advanced nurse practitioners, etc.).
The survey (full instrument can be found in the Additional file 1) presented three genetic test report scenarios for
interpretation: a genetic risk for diabetes, genomic sequencing for symptoms report implicating a potential HMN7B:
distal hereditary motor neuropathy VIIB diagnosis, and a statin-induced myopathy risk. Participants were also asked
about their opinions on DTC-GT results and rank their own perceived level of preparedness to review genetic test
results with patients.
Results: The rates of correctly interpreting results were relatively high (74.4% for the providers compared to the
specialist’s 83.4%) and age, prior genetic test consultation experience, and level of trust assigned to the reports were
associated with higher correct interpretation rates. The self-selected efficacy and the level of preparedness to consult
on a patient’s genetic results were higher for the specialists than the provider group.
Conclusion: Specialists remain the best group to assist patients with DTC-GT, however, primary care providers may
still provide accurate interpretation of test results when specialists are unavailable.
Keywords: Precision medicine, Commercial genetics, Direct-to-consumer genetic testing, Primary care, Genetic
counseling
*Correspondence: smcgrath@unomaha.edu
1School of Interdisciplinary Informatics, University of Nebraska at Omaha, 1110
S 67TH St., 68182 Omaha, NE, USA
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
McGrath et al. BMC Health Services Research          (2019) 19:844 Page 2 of 12
Background
Availability of Direct-to-Consumer genetic testing (DTC-
GT) has grown in the United States over the past decade,
and they have recently started to cross over from a
niche product to something with mainstream appeal [1].
Interest in DTC-GTs, which are available online from
company websites and major retailers like Amazon, have
been accelerating. In fact, the DTC-GT kit sold by
23andMe was one of the top 5 best sellers for Amazon’s
Black Friday sale in 2017 [2]. The number of DTC-GT kits
sold offering ancestry results has doubled since 2017, with
over 12 million kits sold [3]. Despite the growing inter-
est and use of DTC-GT kits, only 10-20% of DTC-GT
customers had shared their genetic test results with pri-
mary care physicians [4, 5]. Previous studies have shown
that the typical consumer of DTC-GTs held both higher
levels of education and pay in contrast to the average
American citizen [4, 6]. As the consumers of these tests
continue to shift from hobbyists to the general public, it
is likely that more individuals will request assistance in
interpreting their results. Previous research has shown
that physicians feel ill prepared to educate patients about
genetic test results [7–11]. Presently, there is a knowledge
gap in how accurately primary care providers can inter-
pret and communicate genetic test results to patients in
comparison to genetic specialist. There have been some
previous studies which have focused on primary care
providers and genetics [12–15] but our study is novel
in that it samples a larger cohort of genetic specialists
(n=165) and non-genetic providers (n=99). This allows us
to provide more robust measurements of interpretation
differences between genetic specialists and non-genetic
specialists compared to prior studies. Globally, patients
from Australia, Germany, United States, and elsewhere
have expressed a preference for some form of regulation
of DTC-GT and for physician assistance in interpret-
ing this kind of data [16–18]. Purchasing DTC-GT is
an elective process for someone to opt-in to, inputting
genomic data into patient records will switch gears to
an opt-out process. We are approaching a period of time
where physicians encountering patients bringing in their
DTC-GT reports will shift to genomic results appear-
ing in the majority of all their patient’s EHRs, thanks
in part to projects like the Precision Medicine Initiative.
Studies like the Clinical Sequencing Exploratory Research
Consortium (CSER) [19] and the electronic MEdical
Records and GEnomics (eMERGE) network have been
working on integrating genomic medicine into clinical
care for several years now. eMERGE has been com-
bining EHRs and genomics to improve discovery and
patient care since its launch in 2007 [20, 21]. Now in
its third round of funding, eMERGE is generating clini-
cally actionable results to return to patients in the EHR
[22, 23] The CSER Genetic Counseling Working Group
(GCWG) was launched in 2012 and is dedicated to assist-
ing genetic counselors with challenges encountered with
genomic medicine (genomic education, results disclosure,
and other issues) [19]. As work progresses on these issues,
the line separating clinical genetic testing and DTC-GT is
becoming harder to define [24]. Recognizing the current
and future need for integration of genomic data into the
EHR, the two largest EHR vendors, Epic and Cerner have
recently enabled their systems to store structured genomic
data in the patient record [25, 26].
The United States based Precision Medicine Initiative
(PMI) established $215 million to help actualize precision
medicine in 2015 [27]. Patient genetic data for individuals,
information about their lifestyle, and environmental data
would be directly incorporated into diagnosis and treat-
ment recommendations in addition to the standard family
and patient histories currently found in medical records.
Precision medicine requires the collection of robust, mul-
tifaceted biomedical data sets; therefore, a major task of
the initiative is to recruit a million volunteers to help
capture this necessary data. A wide range of data types
would be collected from this cohort, including genetic
and microbiome sequencing, lifestyle data, metabolites,
and information from wearable sensors. As of June 2017,
beta testing for this program, now known as All of Us,
has begun [28]. One component of the PMI initiative is
to incorporate more patient genetic data into EHRs. This
action should facilitate data analysis and inter-operability,
which means medical providers need to be able to accu-
rately and confidently interpret genetic information for
patients.
As we see a shift from DTC-GT over to more genetic
results piped into the EHR, clinicians will be increas-
ingly called upon to interpret and act on results. With
the growing consumer interest in DTC-GT [24] there
is a shortage of trained specialists needed to meet this
demand [29]. Thus, primary care physicians will likely be
asked to interpret DTC-GT results with increasing fre-
quency. Some primary care providers have already begun
helping their patients interpret genetic test results [30].
Success will be defined by the ability of these physicians
to properly communicate results and risks identified from
genetic and genomic tests back to their patients. Many
DTC-GT results relate to small risk changes for com-
mon diseases and pharmacogenetics, which may be more
appropriately interpreted as part of primary care and may
not require a visit to a genetics specialist. Failure in this
task will erode the fundamental clinical value proposed by
precision medicine. The complexity of these tests is one
of the reasons the American College of Medical Genetics
and Genomics has recommended that genetics experts
be made available for patient test result consultations
[31]. Based off professional memberships and certifica-
tion in the United States, there are only 4,244 genetic
McGrath et al. BMC Health Services Research          (2019) 19:844 Page 3 of 12
counselors [32] and 1,302 clinical geneticists [33] cur-
rently employed across the nation, numbers that may be
insufficient to meet the potential future demand. Genetic
counselors have advanced training inmedical genetics and
counseling to help patients with education and interpret-
ing genetic test results [34] and are often the first point
of contact for a patient with a suspected genetic con-
dition or test result. Clinical genetics is a certification
offered to physicians by the American Board of Medical
Genetics and Genomics. Clinical geneticists are trained
to diagnose and treat genetic conditions and work coop-
eratively with genetic counselors across the entire range
of genetic disease [35]. Increased market demand may
lead to more genetic counselors and medical geneticists
entering the field; however presently there is a short-
age of genetic counselors engaged in direct patient care,
which may not be fully resolved until 2024-2030 based off
current projections [29].
As precision medicine and genetic testing expand, pri-
mary care providers may be increasingly relied upon to
interpret results for patients. There are efforts underway
to help adapt physician training in anticipation of the
genomic element of precision medicine [36], but the for-
mal systems and tools to assist with this task are still
being developed [37, 38]. Establishing a benchmark on the
ability of physicians to interpret these results will aid in
the development of these tools. However, there has been
no study examining if medical providers can accurately
interpret DTC-GT results for patients when compared to
specialists, or whether they feel prepared to provide DTC-
GT interpretation to patients. Therefore, the purpose of
this study was to understand healthcare providers’ genetic
self-efficacy, their ability to interpret genetic results, and
establish how prepared they feel to accomplish this task.
We adapted with permission a survey instrument [6] that
was designed to understand consumer comprehension of
DTC-GT. Therefore we polled primary care providers and
genetic specialists on the following aims: how each group
interprets genetic test results; determine their confidence
and self-efficacy of interpreting genetic test results with
patients; and capture their opinions and experiences with
DTC-GT. Our hypothesis is that there is a discernible
difference between the two groups in interpretation of
DTC-GT results and how prepared they feel to undertake
this task.
Methods
The online survey was comprised of 33 questions. This
survey was modeled with permission from the Ostergren
study, which evaluated consumer comprehension of DTC-
GT [6]. We selected two of the four scenarios presented in
Ostergren’s survey and added a third case that represented
a more complicated clinical test with a patient facing
report to assess their performance in a more complicated
scenario. Face validity for our study was achieved by hav-
ing two subject matter experts review the questions for
accuracy and have a separate expert on question con-
struction review the survey instrument. There were three
phases to the survey. The first phase collected demo-
graphic information and assessed genetic self-efficacy.
The second phase tested the participant’s ability to accu-
rately answer questions on three genetic interpretation
scenarios. The final phase collected their opinions on the
trustworthiness of DTC-GTs and how prepared they felt
to discuss these results with patients. A free text box for
feedback was offered at the end of the survey. This lat-
ter data was not qualitatively analyzed, but it did provide
some contextual information for the results.
Targeted populations
Participants were recruited from two populations: “Spe-
cialists” (genetic counselors and clinical geneticists),
and “providers” (primary care healthcare providers). We
define primary care providers (PCP) following the defi-
nitions outlined by the Agency for Healthcare Research
and Quality (AHRQ) and US Health Resources and Ser-
vices Administration, which state that “medical specialties
that could meet the criteria for a PCP include general
and family medicine, general pediatrics, general internal
medicine, and geriatrics.” [39]. The AHRQ also includes
nurse practitioners and physician assistants in their def-
inition of primary care providers [40]. Specialists were
recruited through the National Society of Genetic Coun-
selors and direct email solicitation. Primary care health-
care providers were recruited through email, professional
societies (SGIM, AMIA, AAPA, AANP), web fora (Red-
dit), social media (Twitter, Facebook, and Fig. 1). Primary
care providers included a variety of specialties including
internists, family medicine, nurse practitioners, physician
assistants and others. The full breakdown of providers
polled is defined in Table 1. Group selection was made
on the basis that one group is highly specialized in inter-
preting results and educating patients on this topic, and
the other for their high probability of being the first medi-
cal provider patients ask to assist in interpreting DTC-GT
results. These two groups are hereto referred to as the spe-
cialist group for those with certification in genetics-based
practice (genetic counselors and clinical geneticists) and
providers for the primary care providers.
Genetic self-efficacy
Genetic self-efficacy was measured on a six-point Likert
scale (1 = Strongly agree to 6 = Strongly disagree) across
five questions. Following the design of the Ostergren
study, the self-efficacy questions were adapted from the
six-item measure of genetic self-efficacy by Kaphingst
[41, 42]. The only modification to Kaphingst’s instrument
was the exclusion of the first question: “I am able to
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Fig. 1Map of participants across the United States, built with Tableau version 2019.1. Additional details and views can be found at https://public.
tableau.com/views/Mapofparticipants/Dashboard1
understand information about how my genes can affect
my health”. Strong internal consistency across the five
questions was shown with a Cronbach’s alpha of 0.97 for
the specialists and 0.92 for the providers.
Scenario testing
Three test scenarios were developed to model three
aspects of DTC-GT results: disease risk, genetic symp-
toms testing, and drug response. Each scenario question
included a best interpretation answer, and an interpreta-
tion score was generated by calculating the total number
of correct over the three scenarios for a scale of 0-6. Scores
were interpreted in aggregate, with no weighting, as has
been done in prior studies [4–6, 43]. Scenarios 1 and 3 are
identical to the ones used in the Ostergren study. The first
scenario was modeled off a disease risk report from the
company 23andMe. It presents a DTC-GT result for a 35-
year old male, classified as obese, and his genetic suscep-
tibility for diabetes (3 questions). The third scenario was
a genetic drug response result from the company Pathway
Genomics. It presents risk level for statin-inducedmyopa-
thy for a male (age unspecified) taking the statin drug
simvastatin to control his cholesterol (1 question). The
second scenario was a novel scenario constructed using
the patient generated report from a genomic test tool,
COMPASS™, developed at Geisinger [44] which presents
the result of a clinical genetic test. COMPASS™generates
two different reports: a patient focused report and a
provider focused report. The second scenario was con-
structed using results from the patient version of the
report. The scenario presented the symptoms report for a
48-year old woman with three children. In order to help
diagnose her symptoms, a genetic sequencing test was
ordered. From that test, DCTN1 is highlighted as note-
worthy, because a variant of this gene can cause HMN7B:
distal hereditary motor neuronopathy type VIIB, which
matches some of her symptoms (2 questions).
Opinion analysis
Opinions of the two groups were compared across three
different categories: patient concern, DTC tests, and
genetic self-efficacy. For the patient concern questions,
survey participants were asked to rate the level of con-
cern the patient should have based off the diabetes and
HMN7B test results. In the DTC category, they were asked
to rank how trustworthy were each scenario’s information
(5 point Likert, 1 = Highly Trustworthy, 3 = Neutral, 5 =
Highly Untrustworthy), which we refer to as the trustwor-
thiness variable. The second half of the DTC test category
asked how prepared they personally felt to discuss
DTC-GT results with patients (5-point Likert, 1 = Well
prepared, 3 = Neutral, 5 = Very unprepared), which we
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Table 1 Participant Demographics (n = 264)
Total Provider Specialist
Mean age± SD (range), years 39.9 ±13.7 (21-81) 48.9 ±14 (21-81) 34.6 ±10.3 (23-75)
Years practicing 12.4 ±11.8 (1-50) 18.7 ±12.7 (1-50) 8.6 ±9.2 (1-47)
Gender
Male 19.7% 39.4% 7.8%
Female 80.3% 60.6% 92.2%
Race
White 90.1% 88.9% 90.9%
Asian 5.0% 5.1% 4.9%
Black or African American 0.7% 2.0% 0.0%
Two or more races 1.2% 1.0% 1.2%
Did not wish to self identify 0.7% 1.0% 0.6%
Ethnicity
Hispanic or Latino 2.3% 2.0% 2.4%
Medical Specialty
Internal Medicine 9.5% 25.3%
Primary care (MD) 6.8% 18.2%
Nurse Practitioner 6.1% 16.2%
Family medicine (MD) 5.7% 15.2%
Physician Assistant 5.3% 14.1%
Other∗ 2.3% 6.1%
Emergency Medicine 1.9% 5.2%
Genetic Counselor 61.0% 97.6%
Clinical Geneticists 1.5% 2.4%
Work Environment
Hospital 42.8% 26.3% 52.7%
Clinic 14.0% 15.2% 13.3%
Group Practice 9.8% 20.2% 3.6%
Integrated Healthcare Delivery System 8.7% 13.1% 6.1%
Laboratory 6.4% 10.3%
Employed Physician Practice 6.4% 12.1% 3.0%
University Medical Center 3.0% 4.0% 2.4%
Academia 1.9% 3.0% 1.2%
Solo Practice 1.5% 1.0% 1.8%
Other 1.5% 2.0% 1.2%
Clinical Research 1.1% 1.8%
Health Center 1.1% 3.0%
Industry 0.8% 1.2%
Telecommute 0.8% 1.2%
*Medical oncology, clinical research, endocrinology, pediatric sports medicine, and infectious diseases
refer to as the preparedness variable. Genetic self-efficacy
scores, or their innate abilities to understand and dis-
cuss genetics, were aggregated from 5 questions with a 1
equaling a “strongly disagree” and a 6 equaling a “strongly
agree”.
Data analysis
SPSS version 22 was used for statistical analysis and
Tableau Desktop version 2018.1.4 was used to construct
data visualizations. Cronbach’s alpha was used to exam-
ine the internal consistency of participant’s answers on
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the self-efficacy questions. A low Cronbach’s alpha score
would indicate contradicting answers to the questions; for
example, stating high confidence in their ability to explain
to others about how genes affect one’s health, but a low
confidence in knowledge on how genetics may influence
risk for disease. Chi-square analyses were used to compare
interpretation scores from the three scenarios. We looked
at two different analyses, one to analyze total scores from
all six-interpretation scores, and another to inspect each
question individually.
Binomial logistic regression was performed on seven
variables to assess the effects of grouping (specialist or
provider), age, number of years practicing medicine, prior
DTC test result consultations (Y/N), trustworthy variable,
prepared variable, and average genetic self-efficacy scores
on the likelihood of several outcomes (total interpretation
scores, and scores on individual questions). Linearity of
the continuous variables with respect to the logit of the
dependent variable was assessed via the Box-Tidwell pro-
cedure [45]. A Bonferroni correction was applied using all
seven terms in the model resulting in statistical signifi-
cance being accepted when p < .007 [46]. Based on this
assessment, six continuous independent variables were
found to be linearly related to the logit of the dependent
variable. One variable required transformation: years of
practice. A “reflect and inverse” transformation was per-
formed due to extreme left skew to the data, driven by
a high percentage of participants who listed only 1 year
in practice. Multicollinearity among independent vari-
ables was assessed using the standard errors for the β
coefficients with a threshold of >2.0 to detect poten-
tial outliers. Cases where the studentized residual with
a values of exceeding 2.75 standard deviations and were
removed are documented. The interpretation sum score
was dichotomized into higher and lower comprehension
through a median split procedure, with lower comprehen-
sion (below or equal to the median of 5; n = 208) or higher
comprehension (6 out of 6; n = 56) groups. The regression
method used was a stepwise backward logistic regression
(Backward: LR) for removing variables in themodel. Back-
ward LR starts with all variables and uses the likelihood
ratio test to determine which variables are removed to
improve the model.
Results
Demographics
427 surveys were initiated and 264 completed (62%
completion rate) with a response rate of 9.1% (427 out of
4,697). Gender ratios were significantly skewed (p < .01)
towards females both in the total (19.7% male and 80.3%
female) and between groups. This may be due to sampling
professions which are majority female: genetic counselors
(96% of the field is female [47]), nurse practitioners (88%
female [48]), and physician assistants (63% female [49]).
Combined, these three groups accounted for 72.4% of the
surveyed professions. Over 90% of respondents identified
as white, non-Hispanic or Latino.
Result interpretation
A comparison of scenario interpretation scores between
the two groups found the providers averaged 74.4% cor-
rect compared to the average of 83.4% by the specialists
(p < .001). Both groups performed better in scenarios
1 and 3, while lower in scenario 2. Figure 2 provides
additional details on the how each group interpreted the
provider and specialists scored each individual case.
Opinion analysis
The results presented in Fig. 3 shows the genetic special-
ists had high self-efficacy in their ability to discuss genetic
Fig. 2 Interpretation rates by group across the six scenarios. The proportion that had a correct interpretation is depicted in green, while selection of
the other offered answers are in shades of grey. Additional details and views of the graph can be found at https://public.tableau.com/views/
TestingInterpretation/Dashboard1
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Fig. 3 Participants opinion analysis. Additional details and views can be found at https://public.tableau.com/views/Surveylikert/Dashboard3
results with patients (X̄ = 5.6±1.15) and a Cronbach’s
alpha test showed strong internal consistency (0.974).
Provider’s self-efficacy was slightly lower (X̄ = 4.6±0.84,
Cronbach’s alpha = 0.918). Genetic specialists were more
confident in their ability to discuss DTC results with
patients (X̄ = 4.3±1.0) compared to the providers (X̄ =
3.0±1.2), which was statistically significant (p < .001).
When asked if they had encountered patients who had
brought in their personal DTC-GT results, 57.9% of
the specialists said yes (with an average number of 5
patients) compared to the 17.2% of providers (averaging
2.5 patients).
Regression analysis
Several binomial regression models were run from the
results. The first case was evaluating everyone who scored
6 out of 6 in the interpretation tasks (Table 2). The logis-
tic regression model was statistically significant, χ2(7) =
23.31, p < .001. The model explained 16.9% (Nagelkerke
R2) of the variance in test interpretation and correctly
classified 81% of cases. Of the eight-predictor variables
in the model, only four were statistically significant: age,
those who were either neutral about or trusted the DTC
reports, and prior DTC test consultations (as shown in
Table 1). The area under the ROC curve was .729 (95%
CI, .659 to .80), which is an acceptable level of discrimina-
tion according to Hosmer [50]. Those with prior exposure
to DTC test from patients were 2 times more likely to
properly interpret the scenarios than those who have not
had patients bring in their results. Those who ranked their
level of trust as neutral or trustworthy were 3.2 to 3.8
times respectively more likely to properly interpret the
cases than those with stronger opinions or those who dis-
trusted the reports. Increasing age was associated with
a small decreased likelihood of properly interpreting the
scenario by a factor of 1.04.
We also ran a subsequent analysis on the individual sce-
nario questions. When looking for predictors of who cor-
rectly interpreted the HMN7B question 1 (Erin’s chances
of HMN7B), the model was statistically significant,
Table 2 Summary of logistic regression for scoring highly (6/6) on interpretation tasks (n = 253*)
Variables B S.E. Wald Df Sig Odds Ratio 95% C.I. for Odds Ratio
Lower Upper
Age -0.04 0.02 6.12 1 0.01 0.96 0.93 0.99
Trustworthy 5.98 4 0.2
Highly Untrustworthy -19.25 22353 0 1 1 0 0 .
Highly Trustworthy -18.32 13481 0 1 1 0 0 .
Neutral 1.18 0.56 4.55 1 0.03 3.27 1.1 9.69
Trustworthy 1.35 0.56 5.84 1 0.02 3.87 1.29 11.62
DTCCustomers(1) 0.71 0.35 3.99 1 0.046 2.03 1.01 4.06
EfficacyAve -0.24 0.18 1.7 1 0.19 0.79 0.55 1.13
Constant -0.89 0.8 1.22 1 0.27 0.41
Note: 6 participants from the original 264 did not answer the trustworthy question and thus were not included in this regression; 5 participants were removed as outliers for
having studentized residuals >2.75
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χ2(9) = 42.62, p < .001. The model explained 21%
(Nagelkerke R2) of the variance test interpretation and
correctly classified 71% of cases. Age (odds ratio 1.04,
p = .03) and Trustworthy (odds ratio 67.99, p = .01) were
again present, but prior exposure to DTC-GT (factor of
3.7, p = .046) was replaced by if they had indicated a
neutral opinion assessing how prepared they felt to assist
patients with their genomic results. The HMN7B scenario
presented a unique case that is explored in the discussion.
Discussion
One of the goals of precision medicine is to include
genomic data in patient records. With the limited num-
ber of specialists in the field, primary care providers will
be the most likely candidates to meet demand as precision
medicine data becomes more widely available. However,
there is a knowledge gap on how well healthcare providers
interpret genomic test data in comparison to those with
focused training in genetics. Prior studies have shown that
primary care physicians can manage genetic test results
appropriately [12, 13] and they have some level of con-
cern about how prepared they are to do so [14]. Our
findings support the position that genetic specialists are
currently best suited to assist patients with interpreting
genetic test results. However, given the relatively modest
differences in two of the three scenarios, providers may be
able to accurately interpret genomic test results when spe-
cialists are unavailable, especially related to polygenic risk
and pharmacogenomics. This may be because clinicians
are trained to apply multifactorial clinical risk factors to
patient decision making and use clinical information such
as allergies and renal function to inform medication use.
This is in contrast to the rare genetic disease scenario
where non-genetic providers are less likely to have exten-
sive experience. Based on the survey results, specialists
are more confident and feel better prepared to perform
genomic test interpretation in comparison to primary
care providers, although the relatively small number of
providers surveyed suggests that additional investigation
is warranted.
Seeing age as a predictor in our regression analysis is not
terribly surprising. It has been 15 years since the initial
completion of the Human Genome project, and its impact
has been immense. While medical education curricula
are being adapted to include more genomic training, this
has only started in earnest over the past ten years [36].
Physicians who completed their medical degree prior to
2007may have had limited exposure to genetics education
compared to those who graduated after 2007. Continuing
education (CE) programs can help to increase knowledge
in this topic. However, if genetics was excluded during
specialization training, many providers may not prioritize
taking CEs in genetics-based topics. According to adult
learning theory, education is most effective when there is
a recognized need to learn a subject and there is a desire
to learn it [51, 52]. Therefore, those who lack exposure
to genetics may have difficulty recognizing the benefits of
taking genetic-based CEs, and thus will fail to seek them
out. This is important given that the current study found
previous experience discussing these kinds of reports was
a factor in predicting higher interpretation scores. Those
who had patients bring in reports tended to do better
than those who have not. This supports the need for more
exposure to genetics during medical school and residency
programs.
Of particular note is the higher level of trust indicated
by the providers group in comparison to the specialists,
even though the specialists felt much more prepared to
discuss results with patients. When evaluating the impact
of the trustworthiness of DTC-GTs on the regression anal-
ysis, having a degree of skepticism may have helped. As
one participant put it “whether I think the data is accu-
rate, the answer is generally yes, but if you were asking do
I think the descriptions and recommendations are com-
prehensive, the answer is no”. The provider group was
generally more trusting of the tests, with less than 10% of
the providers answering in the negative (untrustworthy or
highly untrustworthy). This is in contrast to the 38.4% of
specialist who had a negative level of trust. The specialists
were also much less likely to indicate “highly trustworthy”
(1.3%) than the providers who had selected that option
(7.1%). Those who selected either “neutral” or “trustwor-
thy” comprised the majority of both group (83.8% of the
providers, 74.9% of the specialists, Fig. 3). In order to con-
textualize this properly, one has to consider the exponen-
tial pace at which genetic discoveries are occurring and
thus are opening more frontiers to be explored than we
have answers to. Consider that a recent study found that
the average person has 54 genetic mutations that should
be considered lethal, but don’t appear to harm their health.
Under closer examination of this finding, it is hypothe-
sized these mutations are errors in misclassification in the
literature and/or in databases instead of genotyping error
[53]. This discovery was uncovered via the Exome Aggre-
gation Consortium (ExAC) database [54], which houses
“60,706 unrelated individuals sequenced as part of various
disease-specific and population genetic studies”. In 2016,
Lek et al. also found 192 genetic variants that were thought
to be pathogenic, which turned out to be relatively com-
mon. ExAC has provided much needed population level
allele frequency data that has helped to reduce the bias
related to affected family studies. This underscores how
our comprehension of human genetics is still evolving,
which should instill a sense of caution. As put by Dr.
Isaac Kohane at Harvard Medical School “We really have
a perfect storm of insufficient data and insufficient com-
petence” in regards to physicians interpreting DTG-GT
results [55]. Hence, when evaluating the level of trust
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that appears appropriate for DTC-GT, we can apply the
Russian proverb popularized by Ronald Reagan, “trust, but
verify”, an approach that parallels current FDA policies
[56].
The high level of correct interpretation seen in the
diabetes and drug risk is plausibly attributed to famil-
iarity with these topics in these groups of providers and
specialists. Scenario 2 provided a unique contrast, since
COMPASS™is not a DTC-GT product. The HMNS7B sce-
nario is typically encountered with less frequency as it
represents a rare genetic disease and proved more chal-
lenging than the other scenarios. As a result, interpre-
tation rates started to diverge between the two and we
witnessed a drop in overall interpretation accuracy. We
attribute part of these results as an artifact of the sur-
vey design. Our survey presented screenshots of reports,
which are closer emulations of printed-paper reports than
a more common web-based format. This provided partic-
ipants with a limitation in the way they could interact and
explore the data. Some specialists expressed frustration
with this limitation in the free text feedback. A common
refrain was the expressed desire for more information to
assist in interpreting scenario 2, which was limited due to
the static, non-interactive design of the scenarios. When
evaluating the HMN7B report one participant expressed
concern that it “never said how variant was classified with
clarity”[sic]. The desire to delve deeper into the report and
research the clinical significance of the variant in ClinVar
[57] was expressed by several specialists. One participant
commented that it was “alarming how much information
the DTC reports give without giving any sort of context
of the nuances that go into interpreting results”, several
others also mirrored this concern about patient compre-
hension given the complexity and high reading level of
some of the results. As designed, the COMPASS reports
would be integrated into the electronic health record, with
the ability to dynamically interact with the findings and
provide links to help explain the decision process behind
the reports. However, a key take away here is highlight-
ing the nuance and challenge in presenting infrequent
or rare genomic results, particularly when results are
not straightforward. Specialists demonstrated heightened
levels of scrutiny as demonstrated by their trustworthi-
ness answers and feedback from scenario 2. The provider
group appears to be more willing to accept genetic testing
results at face value.
This creates a challenge for developing mechanisms to
provide results back to clinicians in a meaningful fash-
ion. Informatics tools for genetic consultations need to
correctly highlight relevant information, preferably in an
interactive format, and provide actionable options to its
end users. However, not all genetic test results are eas-
ily interpreted, and determining the clinical relevancy
of many genetic variants is an ongoing challenge as
evidenced by the Clinical Genome Resource (ClinGen)
project [58]. Heritability (the variance in phenotypic traits
between individuals and a population) can have a large
confounding impact on clinical decisions. In the case of
well annotated variants associated with high probabili-
ties of developing aggressive and often fatal cancers, such
as BRCA1 and BRCA2 and hereditary breast and ovar-
ian cancer, clinical decisions are fairly clear. However,
in cases where the relevance is less clearly defined, there
is a potential for greater uncertainty for interpretation.
As mentioned earlier by a participant, there is a “nuance”
to interpreting these tests. Understanding the methodolo-
gies and research cited to support the results presented
appears to be desired by some specialists. This is infor-
mation that may be overwhelming and less useful to
patients who are not equipped to properly critique this
data. Hence, it can be a precarious balancing act of dis-
tilling the information to the right level, which proves
meaningful to both patient and providers.
Previous studies have examined the levels of DTC-
GT customer comprehension of genetic results, and have
found 72-79% were able to correctly interpret DTC-
GTs (4-6) [4–6]. By sampling some of the same ques-
tions as described previously in the Ostergren study [6]
(scenarios 1 & 3), we were able to compare our results with
that study. Of this subset of scenarios, their study reported
81.8% of DTC customers surveyed were able to properly
interpret their scenario questions. For the same four ques-
tions, 91.3% of the combined healthcare cohort (n=264)
correctly interpreted them, which was a difference in pro-
portion of 0.095, p < .001. One distinction to keep in
mind is that customers of DTC-GT have been found to
be more highly educated, and earn more than the median
income in the US [4, 6]; therefore comprehension scores
may dip when we move away from people who have both
the disposable income and are curious enough to purchase
DTC-GTs and we start to see a closer reflection of the
public at large.
There are some limitations of this study, which war-
rant discussion. Response rate for the survey were low
(9.1%), leading to a potential non-response bias. Two fac-
tors suspected to account for the low response rate include
survey length (15 minutes to finish on average supported
by the high abandonment rate) and lack of financial com-
pensation for completions, which is a common practice
to increase physician response rate on surveys. Balancing
the number of questions to include in the survey with
the length of the survey was a challenge but provid-
ing participants exposure to a variety of genomic results
(disease risk, symptoms testing, and pharmacogenomics)
was deemed important. Future work on this topic could
be improved by increasing the sample size of primary
care providers and clinical geneticists. The number of pri-
mary care providers sampled for this survey is small in
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comparison to the total number employed in the United
States. In 2010, the were an estimated 209,000 primary
care physicians, 56,000 nurse practitioners, and 30,000
physician assistants [40]. Additional work to improve the
response and completion rates, while supporting diverse
DTC-GT scenarios is warranted. When running the
regression model to predict those who scored three or less
on the interpretation task, it should be pointed out that
very few participants selected the “highly untrustworthy”
option (n=3), the vast majority who were wary of the tests
elected to use “untrustworthy” (n=44). Having only three
responses may not extrapolate the finding to the wider
population of healthcare providers.
Conclusions
The findings of this study indicate that specialists
remain the best group to assist patients with DTC-GT,
however, primary care providers may still provide accu-
rate interpretation of test results when specialists are
unavailable. The emerging challenge is how to tackle the
infrequent or rare genomic results. Tasking specialists to
address those results with non-specialist providers assist-
ing with the more common cases is one solution. This
is being actively explored by the Consent & Disclosure
Recommendations (CADRe) working group of ClinGen
[59]. The association of age as a predictor for correct
interpretations suggests that younger providers are better
prepared to take advantage of the new data being gener-
ated by precision medicine. There is an opportunity for
developing training approaches to help close any gaps that
appear due to training as genomic data begins to be inte-
grated into EHRs. It is also encouraging that there was a
positive association between prior experience consulting
DTC-GT patients and interpretation scores. This suggests
that increased exposure to these tests may lead providers
to seek additional information to aid in interpretation and
counseling further developing the skill to interpret them.
This will help develop trust in these reports as an effec-
tive tool in patient consultations. Precision medicine is
still in its infancy; however, our findings indicate that
both providers and specialist are positioned to be able to
take advantage of the promise of precision medicine as it
matures and becomes more commonplace.
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